Treatment of multiple myeloma with nasal spray calcitonin: a histomorphometric and biochemical study.

Rico H, Hernandez ER, Diaz-Mediavilla J, Alvarez A, Martinez R, Espinos D

Bone and mineral1 Mar 1990Cited by 17 (Europe PMC)

PMID2322695DOI10.1016/0169-6009(90)90108-rPepBankPUB-02322695

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In multiple myeloma, trabecular bone volume increased significantly during salmon calcitonin treatment.
In plain wordsIn multiple myeloma, trabecular bone volume increased significantly during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
IncreaseTrabecular bone volume
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Measurements
P value
< 0.01
calcitonin group
Source sentences
Summary
In the group treated with calcitonin there was a significant increase (P less than 0.01) in trabecular bone volume, cortical thickness, osteoid volume and osteoid seam thickness index and the osteoclast resorption surface fell significantly (P less than 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269501
02HumanNon-randomized trialEfficacy outcome
In multiple myeloma, cortical thickness increased significantly during salmon calcitonin treatment.
In plain wordsIn multiple myeloma, cortical bone thickness increased significantly during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
IncreaseCortical thickness
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Measurements
P value
< 0.01
calcitonin group
Source sentences
Summary
In the group treated with calcitonin there was a significant increase (P less than 0.01) in trabecular bone volume, cortical thickness, osteoid volume and osteoid seam thickness index and the osteoclast resorption surface fell significantly (P less than 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269502
03HumanNon-randomized trialEfficacy outcome
In multiple myeloma, osteoid volume increased significantly during salmon calcitonin treatment.
In plain wordsIn multiple myeloma, unmineralized bone volume increased significantly during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
IncreaseOsteoid volume
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Measurements
P value
< 0.01
calcitonin group
Source sentences
Summary
In the group treated with calcitonin there was a significant increase (P less than 0.01) in trabecular bone volume, cortical thickness, osteoid volume and osteoid seam thickness index and the osteoclast resorption surface fell significantly (P less than 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269503
04HumanNon-randomized trialEfficacy outcome
In multiple myeloma, osteoid seam thickness index increased significantly during salmon calcitonin treatment.
In plain wordsIn multiple myeloma, the unmineralized bone seam thickness index increased significantly during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
IncreaseOsteoid seam thickness index
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Measurements
P value
< 0.01
calcitonin group
Source sentences
Summary
In the group treated with calcitonin there was a significant increase (P less than 0.01) in trabecular bone volume, cortical thickness, osteoid volume and osteoid seam thickness index and the osteoclast resorption surface fell significantly (P less than 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269504
05HumanNon-randomized trialEfficacy outcome
In multiple myeloma, osteoclast resorption surface decreased significantly during salmon calcitonin treatment.
In plain wordsIn multiple myeloma, the bone surface undergoing resorption decreased significantly during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
DecreaseOsteoclast resorption surface
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Measurements
P value
< 0.01
calcitonin group
Source sentences
Summary
In the group treated with calcitonin there was a significant increase (P less than 0.01) in trabecular bone volume, cortical thickness, osteoid volume and osteoid seam thickness index and the osteoclast resorption surface fell significantly (P less than 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269505
06HumanNon-randomized trialEfficacy outcome
In multiple myeloma, corrected serum calcium decreased significantly during salmon calcitonin treatment.
In plain wordsIn multiple myeloma, corrected blood calcium decreased significantly during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
DecreaseCorrected serum calcium
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Measurements
P value
< 0.001
calcitonin group
Source sentences
Summary
There was also a decline (P less than 0.001) in corrected serum calcium and OHP/Cr, which accounts for the diminished bone resorption.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269506
07HumanNon-randomized trialEfficacy outcome
In multiple myeloma, OHP/Cr decreased significantly during salmon calcitonin treatment.
In plain wordsIn multiple myeloma, the hydroxyproline-to-creatinine ratio decreased significantly during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
DecreaseOHP/Cr
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Measurements
P value
< 0.001
calcitonin group
Source sentences
Summary
There was also a decline (P less than 0.001) in corrected serum calcium and OHP/Cr, which accounts for the diminished bone resorption.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269507
08HumanNon-randomized trialSafety outcome
In multiple myeloma, all patients tolerated salmon calcitonin.
In plain wordsAll patients with multiple myeloma tolerated salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
Not applicableTolerability
Study
n = 11
Outcome group
Adverse events · Whole body
Studied dose
200 IU · intranasal · 3 monthsAs given in this study (human).
Source sentences
Summary
Calcitonin was perfectly tolerated by all patients and our results show it to be useful in the treatment of bone lesions of multiple myeloma.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of calcitonin on the bone lesions of multiple myeloma, we studied 11 patients treated for 3 months with salmon calcitonin in nasal spray (200 IU) and 500 mg of elemental calcium/day.
Summary · context
Pre- and post-treatment biochemical and histomorphometric parameters were compared to those of 12 patients treated for the same time with 500 mg elemental calcium alone.
Summary · context
Both groups received the same hematological treatment.
Report a problemFND-0232269508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.